Subventions financées

As people live longer, our society undergoes rapid demographic change.

In Canada, over 1 million people have been diagnosed with bipolar disorder (BD) in their lifetime.

Cannabis is one of the most commonly used recreational substances in Canada, yet its effects on brain blood flow remain poorly understood.

Depression is one of the most common mental health challenges faced by young people, yet choosing the right treatment remains a process of trial and error.

Optogenetics, defined as a technique where light-sensitive genes are introduced into brain cells to control their activity with light, allows researchers to precisely control nerve cell communication thereby, transforming brain research.

In Alzheimer’s disease (AD), the pathogenic amyloid-beta protein accumulates in the brain parenchyma and vessel walls.

Every day, over 350 Canadians are diagnosed with dementia, and this number is expected to grow rapidly.

Brain cancer is rarely curative and urgently needs novel transformative treatments.

Depression is a leading cause of disability, with a large proportion of treatment-resistant patients. Recent studies have implicated reduced brain inhibition in human depression from a specific neuron type (SST), and new pharmacology boosting this reduced inhibition led to antidepressant and pro-cognitive effects in rodents.

Amyotrophic lateral sclerosis (known as ALS or Lou Gehrig’s disease) is a debilitating disease that causes loss of control over muscles and leads to death quickly after diagnosis.